A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer

Diseases of the Esophagus

Volumn 30, Issue 7, 2017, Pages

  Sanford, Nina N ^a   Catalano, P J ^a   Enzinger, P C ^a   King, B L ^a   Bueno, R ^b   Martin, N E ^a   Hong, T S ^c   Wo, J Y ^c   Mamon, H J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Esophageal cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGE; AGED; ANASTOMOSIS LEAKAGE; ANOREXIA; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHYLOTHORAX; CLINICAL OUTCOME; COMORBIDITY; COMPARATIVE STUDY; CONFORMAL RADIOTHERAPY; DEHYDRATION; DIARRHEA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; ESOPHAGUS STENOSIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENDER; HEART DISEASE; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PERICARDITIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIOTHERAPY DOSAGE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; WOUND COMPLICATION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; PATIENT READMISSION; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 85049038136     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1093/dote/dox025     Document Type: Article

References (17)

1. Siegel RL, Miller KD, Jemal A et al. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30
2. van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-84
3. Shapiro J, van Lanschot J J, Hulshof M C et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-termresults of a randomised controlled trial. Lancet Oncol 2015; 16: 1090-8
4. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-92
5. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7
6. Sjoquist K M, Burmeister B H, Smithers B M et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-92
7. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4
8. National Cancer Institute. Common Terminology Criteria for Adverse Events v4. 0 NCI, NIH, DHHS. May 29, 2009 NIH publication # 09-7473
9. KimMK, Cho K J, Park S I et al. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 115-21
10. Rutegard M, Lagergren P, Rouvelas I et al. Surgical complications and long-term survival after esophagectomy for cancer in a nationwide Swedish cohort study. Eur J Surg Oncol 2012; 38: 555-61
11. van Meerten E, Muller K, Tilanus HW et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006; 94: 1389-94
12. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-33
13. Herskovic A, Martz K, al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-8
14. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005; 23: 2310-7
15. Conroy T, Galais MP, Raoul JL et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014; 15: 305-14
16. Mukherjee S, Hurt C, Gwynne S et al. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/ paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma. J Clin Oncol 34 2016 (suppl 4S; abstr 3) http://ascopubs. org/doi/abs/10. 1200/jco. 2016. 34. 4 suppl. 3
17. Centre Oscar Lambret, National Cancer Institute, France. PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer (PROTECT). In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited Aug 31 2016]. Available from: https://clinicaltrials. gov/ct2/show/ NCT02359968